Research Paper Volume 10, Issue 8 pp 1921—1931
Serum CNPY2 isoform 2 represents a novel biomarker for early detection of colorectal cancer
- 1 Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South ; Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, China
- 2 Department of Experimental Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South ; Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, China
- 3 Department of Clinical Laboratory Medicine, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, China
- 4 School of Mathematics and Computational Science Sun Yat-sen University, Guangzhou, Guangdong, P. R. China
- 5 Senboll Biotechnology Co., Ltd., Pingshan Bio-Pharmacy Business Accelerator, Pingshan District, Shenzhen, Guangdong 518000, P. R. China
received: July 12, 2018 ; accepted: July 27, 2018 ; published: August 2, 2018 ;https://doi.org/10.18632/aging.101512
How to Cite
Copyright: Peng et al. This is an open‐access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Since early diagnosis is very important for treating CRC, we decided to detect peripheral serum canopy fibroblast growth factor signaling regulator 2 (CNPY2) isoform 2 to verify its diagnostic value for CRC patients. Serum samples were collected from 430 CRC patients and 201 healthy controls. Enzyme-linked immunosorbent assay (ELISA) detection kits for CNPY2 isoform 2 were generated and then applied to measure serum CNPY2 isoform 2 concentrations. Serum carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) were also measured. The median serum CNPY2 isoform 2 concentrations in all CRC patients were significantly higher than those in the healthy control group (all P<0.001). Those with stage I CRC presented the highest area under the receiver operating characteristic curve (AUC) for CNPY2 isoform 2 [0.707, 95% confidence interval (CI): 0.649–0.765, P<0.001]. The diagnostic efficiency of the combination of CNPY2 isoform 2, CEA and CA19-9 was significantly higher than that of each biomarker detected separately (all P<0.0167). Serum CNPY2 isoform 2 may be a valuable biomarker for the early detection of CRC and presents an improvement in the diagnostic efficiency by combination of CEA and CA19-9.